- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
Drug guidance
Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
Condition
Liver
2 May 2019
Published on 02 May 2019
Last Updated on 02 May 2019
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Rifaximin 550 mg tablet as add-on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy.
Subsidy status
Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.
Rifaximin for reducing overt hepatic encephalopathy (2 May 2019) [PDF, 467 KB]